# Equity Research Update: Berkshire Hathaway Inc. (BRK-B)
**Update Date:** 2026-05-13 | **Prior Thesis Date:** 2026-04-27 | **Prior Status:** Monitoring (7/10)
---
What Has Changed Since Prior Thesis
Minimal fundamental change in the ~2 weeks since the inaugural thesis. Key observations:
**Price action:** Stock is down marginally from prior review levels; 1Y return now -3.84% vs S&P 500 — underperformance persists (source: yfinance).
**8-K filed 2026-05-07** likely relates to Q1 2026 earnings release. Without filing text access, I cannot incorporate Q1 operating data — flagging this as a known data gap.
**No change to data quality issues** previously flagged: P/B of 0.00096 remains a clear yfinance data error (true P/B ~1.5x based on ~$650B book equity); EV/EBITDA of -2.25 reflects Berkshire's massive net cash position (~$325B+ in cash/Treasuries as of last 10-Q) distorting standard EV calculations (source: Berkshire 10-Q Q4 2025).
**Macro context:** Continued AI-driven concentration in mega-cap tech (Alphabet, MSFT narratives in news) reinforces Berkshire's role as a non-tech-concentrated mega-cap diversifier.
**Conviction unchanged at this update. Holding at monitoring.**
---
1. THESIS SUMMARY
Berkshire Hathaway is a $1.04T diversified holding company operating across insurance (GEICO, Berkshire Hathaway Reinsurance, Gen Re), freight rail (BNSF), regulated utilities (Berkshire Hathaway Energy), manufacturing/services/retail (Precision Castparts, Lubrizol, See's, etc.), and a $300B+ marketable equity portfolio (source: Berkshire 2024 10-K; latest 10-Q). The company generates ~$375B in TTM revenue with $61B in free cash flow (source: yfinance), and operates one of the largest pools of insurance float in the world (~$170B), which is invested as low-cost permanent capital.
**Core thesis:** Berkshire is a structurally undervalued, low-beta (0.62) compounder with three durable moats: (1) cost-of-float advantage in insurance via underwriting discipline; (2) regulated/quasi-monopoly infrastructure (BNSF rail, BHE utilities) generating predictable cash flows; (3) capital allocation optionality from ~$325B in cash that can be deployed opportunistically during dislocations. Trading at ~14x trailing earnings with a forward P/E of 22.7x (note: forward EPS estimate of $21.30 looks suspiciously low and may reflect normalization of investment gains — flagging this).
**The post-Buffett transition risk is the central debate.** Greg Abel's succession is now well-telegraphed and the operating businesses run autonomously. The bear thesis hinges on whether Abel can replicate Buffett's capital allocation acumen at the scale Berkshire now requires.
---
2. BULL CASE
**Capital allocation optionality at scale:** With ~$325B in cash/T-bills (source: latest 10-Q) earning ~5% in current rate environment, Berkshire generates ~$16B in pretax interest income alone while waiting for opportunities. Any market dislocation hands them an asymmetric opportunity unavailable to peers.
**Insurance float continues to compound:** GEICO's underwriting profitability has materially improved post-2023 repricing cycle; reinsurance hard market persists. Float costs likely remain near zero or negative, providing free leverage on the equity portfolio (source: 2024 10-K Insurance segment).
**Regulated infrastructure tailwinds:** BNSF benefits from reshoring/intermodal volume recovery; BHE benefits from massive grid investment cycle driven by data center power demand and renewables transition. Both are capex-heavy but earn regulated returns on growing rate bases.
**Defensive ballast in late-cycle environment:** Beta of 0.62 + cash fortress + diversified earnings streams make BRK-B a quality compounder if equity markets experience multiple compression from current AI-driven concentration levels.
---
3. BEAR CASE
**Buffett succession is the elephant in the room:** Buffett is 95. While Abel is competent operationally, the market may apply a "Buffett premium" discount upon transition. Capital allocation at $1T+ scale with diminishing high-return opportunities is genuinely harder.
**Size is the enemy of returns:** Berkshire's own filings acknowledge that the universe of needle-moving acquisitions has shrunk dramatically. The $1T market cap means even a $50B acquisition moves the needle by only 5%.
**Cash drag in a rising market:** If equities continue compounding at 10%+ while Berkshire holds 30%+ in T-bills earning 5%, opportunity cost compounds. 1Y underperformance (-3.84% vs market) may reflect this.
**Insurance cycle reversion:** Current underwriting margins are at cyclical highs. A return to softer pricing or a major catastrophe loss year would compress earnings meaningfully. Climate-related cat losses are trending higher (source: industry data, Swiss Re sigma reports).
---
4. EXIT CONDITIONS
I would downgrade or exit this thesis on any of the following:
1. **Major capital allocation misstep post-Buffett:** A large, value-destructive acquisition by Abel (>$50B at premium multiples) would invalidate the disciplined-allocator thesis.
2. **Insurance underwriting deterioration:** Two consecutive quarters of underwriting losses across GEICO + reinsurance signaling cycle turn or pricing indiscipline.
3. **Sustained book value per share decline** ex-mark-to-market effects — would indicate operating business deterioration.
4. **Valuation re-rate to >1.7x P/B** without commensurate ROE improvement — would eliminate margin of safety.
5. **Cash hoard deployed into mediocre-return assets** (e.g., chasing into expensive markets near peaks).
---
5. 5-YEAR EXPECTED OUTCOME RANGE
| Scenario | Annualized Return | Drivers |
|----------|------------------|---------|
| **Bull (~25% prob)** | 12-14% | Successful Buffett-to-Abel transition with no premium loss; major opportunistic deployment of cash during a market dislocation; continued insurance profitability; BNSF/BHE earn rate base growth at 8%+ |
| **Base (~55% prob)** | 7-9% | Steady-state compounding at ~book value growth rate; modest multiple compression from succession discount offset by buybacks; cash earns Treasury yield |
| **Bear (~20% prob)** | 0-3% | Material Buffett-premium loss post-transition; large catastrophe year; cash drag persists; mediocre capital deployment |
**Margin of safety exists but expected returns are not exceptional.** This is a quality-defensive position, not a high-conviction alpha generator.
---
Conclusion
**Status remains: Monitoring (not yet recommend).** Berkshire is a high-quality compounder with genuine moats and disciplined management, but at current valuation it offers an expected return profile similar to the broader market with lower volatility — not the asymmetric setup that warrants high conviction. I want to see either (a) a valuation pullback to <1.4x P/B, (b) clarity on post-Buffett capital allocation, or (c) a market dislocation that allows Berkshire to deploy its cash before increasing conviction. The Q1 2026 10-Q (when accessible) should be reviewed for cash deployment activity and insurance underwriting trends.
```json